2015 - Fellow of the Australian Academy of Health and Medical Science
Michael Berk mostly deals with Psychiatry, Bipolar disorder, Internal medicine, Depression and Schizophrenia. His studies in Psychiatry integrate themes in fields like Randomized controlled trial and MEDLINE. His work deals with themes such as Intervention, Mood disorders and Clinical psychology, Mood, which intersect with Bipolar disorder.
His research integrates issues of Endocrinology, Psychosis and Placebo-controlled study in his study of Internal medicine. His Depression research is multidisciplinary, relying on both Odds ratio, Mental health, Prospective cohort study, Risk factor and C-reactive protein. His study looks at the relationship between Schizophrenia and topics such as Pharmacology, which overlap with Adjunctive treatment.
Michael Berk mainly focuses on Psychiatry, Bipolar disorder, Internal medicine, Depression and Clinical psychology. His work on Psychiatry deals in particular with Mood, Schizophrenia, Major depressive disorder, First episode and Mental health. In his study, Clinical trial is strongly linked to Randomized controlled trial, which falls under the umbrella field of Bipolar disorder.
His biological study spans a wide range of topics, including Placebo, Endocrinology and Placebo-controlled study. His Depression research includes elements of Comorbidity, MEDLINE and Anxiety. As part of his studies on Clinical psychology, Michael Berk often connects relevant subjects like Cognition.
His primary areas of study are Bipolar disorder, Depression, Internal medicine, Psychiatry and Randomized controlled trial. He specializes in Bipolar disorder, namely Mania. Michael Berk has researched Depression in several fields, including Mental health, Epidemiology, Disease and Anxiety.
His Internal medicine research incorporates elements of Placebo-controlled study, Placebo, Oncology and MEDLINE. Michael Berk conducts interdisciplinary study in the fields of Psychiatry and Clinical neurology through his research. His Randomized controlled trial research incorporates elements of Meta-analysis, Clinical trial and Adjunctive treatment.
Depression, Bipolar disorder, Internal medicine, Major depressive disorder and Mental health are his primary areas of study. His work carried out in the field of Depression brings together such families of science as Epidemiology, Disease, Bioinformatics and MEDLINE. Psychiatry covers Michael Berk research in Bipolar disorder.
The Major depressive disorder study combines topics in areas such as Guideline, Adverse effect, Dementia and Clinical psychology. Michael Berk works mostly in the field of Mental health, limiting it down to topics relating to Public health and, in certain cases, Reciprocity, Social environment, Gerontology and Urbanization. His Schizophrenia research integrates issues from Adjunctive treatment, Psychosis, Cognition, Neuroprotection and Autism spectrum disorder.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pathways underlying neuroprogression in bipolar disorder : focus on inflammation, oxidative stress and neurotrophic factors
Michael Berk;Flavio P Kapczinski;Ana Cristina Andreazza;Ana Cristina Andreazza;Olivia Dean;Olivia Dean.
Neuroscience & Biobehavioral Reviews (2011)
Oxidative stress in psychiatric disorders : evidence base and therapeutic implications
Felicity Ng;Michael Berk;Michael Berk;Olivia Dean;Ashley I. Bush.
The International Journal of Neuropsychopharmacology (2008)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Lakshmi N. Yatham;Sidney H. Kennedy;Sagar V. Parikh;Ayal Schaffer.
Bipolar Disorders (2013)
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.
Michael Maes;Piotr Galecki;Yong Seun Chang;Michael Berk;Michael Berk.
Progress in Neuro-psychopharmacology & Biological Psychiatry (2011)
So depression is an inflammatory disease, but where does the inflammation come from?
Michael Berk;Lana Williams;Lana Williams;Felice N Jacka;Felice N Jacka;Adrienne O'Neil;Adrienne O'Neil.
BMC Medicine (2013)
Association of Western and Traditional Diets With Depression and Anxiety in Women
Felice N Jacka;Julie A Pasco;Arnstein Mykletun;Lana J Williams.
American Journal of Psychiatry (2010)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009
Lakshmi N Yatham;Sidney H Kennedy;Ayal Schaffer;Sagar V Parikh.
Bipolar Disorders (2009)
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
Lakshmi N Yatham;Sidney H Kennedy;Sagar V Parikh;Ayal Schaffer.
Bipolar Disorders (2018)
The chemistry and biological activities of N-acetylcysteine
Yuval Samuni;Sara Goldstein;Olivia M. Dean;Olivia M. Dean;Olivia M. Dean;Michael Berk.
Biochimica et Biophysica Acta (2013)
The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders
Isabella Pacchiarotti;David J. Bond;Ross J. Baldessarini;Willem A. Nolen.
American Journal of Psychiatry (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: